EE04674B1 - 3-prasoolkarboksamiidi derivaadid, mis omavad afiinsust kannabinoidretseptori suhtes - Google Patents

3-prasoolkarboksamiidi derivaadid, mis omavad afiinsust kannabinoidretseptori suhtes

Info

Publication number
EE04674B1
EE04674B1 EE9800171A EE9800171A EE04674B1 EE 04674 B1 EE04674 B1 EE 04674B1 EE 9800171 A EE9800171 A EE 9800171A EE 9800171 A EE9800171 A EE 9800171A EE 04674 B1 EE04674 B1 EE 04674B1
Authority
EE
Estonia
Prior art keywords
razole
cannabinoid receptor
carboxamide derivatives
affecting
derivatives affecting
Prior art date
Application number
EE9800171A
Other languages
English (en)
Estonian (et)
Other versions
EE9800171A (et
Inventor
Barth Francis
Casellas Pierre
Millan Joseph
Oustric Didier
Rinaldi Murielle
Sarran Martine
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of EE9800171A publication Critical patent/EE9800171A/xx
Publication of EE04674B1 publication Critical patent/EE04674B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EE9800171A 1995-12-08 1996-12-06 3-prasoolkarboksamiidi derivaadid, mis omavad afiinsust kannabinoidretseptori suhtes EE04674B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9514547A FR2742148B1 (fr) 1995-12-08 1995-12-08 Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
PCT/FR1996/001953 WO1997021682A1 (fr) 1995-12-08 1996-12-06 Derives de 3-pyrazolecarboxamide avec une affinite pour le recepteur des cannabinoides

Publications (2)

Publication Number Publication Date
EE9800171A EE9800171A (et) 1998-12-15
EE04674B1 true EE04674B1 (et) 2006-08-15

Family

ID=9485291

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800171A EE04674B1 (et) 1995-12-08 1996-12-06 3-prasoolkarboksamiidi derivaadid, mis omavad afiinsust kannabinoidretseptori suhtes

Country Status (34)

Country Link
US (1) US5925768A (pl)
EP (2) EP0868420B1 (pl)
JP (1) JP3510270B2 (pl)
KR (1) KR100488610B1 (pl)
CN (1) CN1101813C (pl)
AR (1) AR004364A1 (pl)
AT (1) ATE191211T1 (pl)
AU (1) AU718763B2 (pl)
BR (1) BR9611986A (pl)
CA (1) CA2239489C (pl)
CZ (1) CZ294307B6 (pl)
DE (1) DE69607484T2 (pl)
DK (1) DK0868420T3 (pl)
EE (1) EE04674B1 (pl)
ES (1) ES2148820T3 (pl)
FR (1) FR2742148B1 (pl)
GR (1) GR3033626T3 (pl)
HU (1) HUP9901244A3 (pl)
IL (1) IL124801A (pl)
IS (1) IS4765A (pl)
MX (1) MX9804565A (pl)
MY (1) MY115228A (pl)
NO (1) NO310683B1 (pl)
NZ (1) NZ323962A (pl)
PL (1) PL186466B1 (pl)
PT (1) PT868420E (pl)
RU (1) RU2170230C2 (pl)
SI (1) SI0868420T1 (pl)
SK (1) SK283706B6 (pl)
TR (1) TR199801041T2 (pl)
TW (1) TW402594B (pl)
UA (1) UA44913C2 (pl)
WO (1) WO1997021682A1 (pl)
ZA (1) ZA9610299B (pl)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948777A (en) * 1997-03-18 1999-09-07 Smithkline Beecham Corporation Cannabinoid receptor agonists
ATE247097T1 (de) * 1998-05-04 2003-08-15 Univ Connecticut Analgetische und immunomodulierende cannabinoiden
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
BR0009200A (pt) 1999-03-22 2001-12-26 Immugen Pharmaceuticals Inc Compostos e composições para o tratamento dedoenças associada com disfunção imune
AU780572B2 (en) * 1999-10-18 2005-04-07 University Of Connecticut, The Pyrazole derivatives as cannabinoid receptor antagonists
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6900236B1 (en) * 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
DE60033834T2 (de) 1999-10-18 2007-11-15 The University Of Connecticut, Farmington Für periphäre cannabinoid-rezeptoren selektive liganden
US7119108B1 (en) * 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
FR2800372B1 (fr) * 1999-11-03 2001-12-07 Sanofi Synthelabo Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
US6541510B2 (en) * 2000-09-28 2003-04-01 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
AU2001296402A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
CA2435409A1 (en) * 2001-01-26 2002-08-01 University Of Connecticut Novel cannabimimetic ligands
CA2436133A1 (en) 2001-01-29 2002-08-08 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US7067539B2 (en) * 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
EP1414775B1 (en) 2001-07-13 2012-12-19 The University of Connecticut Bicyclic cannabinoid
WO2003007887A2 (en) * 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
AU2002331766A1 (en) * 2001-08-31 2003-03-18 University Of Connecticut Novel pyrazole analogs acting on cannabinoid receptors
US7666867B2 (en) * 2001-10-26 2010-02-23 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
JP2005509032A (ja) * 2001-11-14 2005-04-07 シェーリング　コーポレイション カンナビノイドレセプターリガンド
US20040171613A1 (en) * 2001-12-27 2004-09-02 Japan Tobacco Inc. Therapeutic agent for non-immediate type allergic diseases
WO2003061699A1 (en) * 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedies for allergic diseases
CA2478338A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
WO2003080043A1 (en) * 2002-03-18 2003-10-02 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
EP1539693B9 (en) 2002-06-19 2008-10-08 Schering Corporation Cannabinoid receptor agonists
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
WO2004018434A1 (en) * 2002-08-21 2004-03-04 Glaxo Group Limited Pyrimidine compounds
WO2004017922A2 (en) 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
GB0222495D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
US7765162B2 (en) * 2002-10-07 2010-07-27 Mastercard International Incorporated Method and system for conducting off-line and on-line pre-authorized payment transactions
AU2003267728A1 (en) * 2002-10-18 2004-05-04 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
CN100349862C (zh) 2002-11-25 2007-11-21 先灵公司 大麻素受体配体
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
MXPA05007114A (es) * 2003-01-02 2005-08-26 Hoffmann La Roche Nuevos agonistas inversos del receptor cb1.
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20060172019A1 (en) * 2003-03-07 2006-08-03 Ralston Stuart H Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
TW200505902A (en) * 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
EP1622876A1 (en) * 2003-05-07 2006-02-08 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
FR2856683A1 (fr) * 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
FR2862647B1 (fr) * 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
GB0402357D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402355D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402356D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
US20080261977A1 (en) * 2004-02-23 2008-10-23 Andrew John Eatherton Pyrimidine Derivatives as Cannabinoid Receptor Modulators
JP2007523206A (ja) * 2004-02-24 2007-08-16 グラクソ　グループ　リミテッド Ｃｂ２受容体モジュレーターとしてのピリジン誘導体およびその使用
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
US7750158B2 (en) * 2004-06-22 2010-07-06 Schering Corporation Cannabinoid receptor ligands
WO2006025069A2 (en) 2004-07-12 2006-03-09 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
ATE460415T1 (de) * 2004-11-29 2010-03-15 Warner Lambert Co Therapeutische pyrazoloä3,4-büpyridine und - indazole
US8853205B2 (en) 2005-01-10 2014-10-07 University Of Connecticut Heteropyrrole analogs acting on cannabinoid receptors
CA2594488C (en) * 2005-01-10 2015-04-28 University Of Connecticut Novel heteropyrrole analogs acting on cannabinoid receptors
FR2887550A1 (fr) * 2005-06-24 2006-12-29 Sanofi Aventis Sa Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique
CN101437398A (zh) * 2006-03-10 2009-05-20 詹里恩探索公司 用于治疗肥胖症的大麻素受体拮抗剂/反向激动剂
WO2007121687A1 (en) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
AU2007245733A1 (en) * 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBX cannabinoid receptor modulators and Potassium channel modulators
US20070254863A1 (en) * 2006-04-27 2007-11-01 Jochen Antel Use of CBx cannabinoid receptor modulators as potassium channel modulators
US7763607B2 (en) * 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
US7875647B2 (en) * 2006-09-29 2011-01-25 Green Cross Corporation Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
WO2008075013A1 (en) 2006-12-18 2008-06-26 7Tm Pharma A/S Modulators of cannabinoid receptor
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
EP1985295A1 (en) 2007-04-04 2008-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
CN101314591B (zh) * 2007-05-30 2010-09-29 上海阳帆医药科技有限公司 吡唑类高选择性大麻受体-1拮抗剂和/或反向激动剂
FR2916758B1 (fr) * 2007-06-04 2009-10-09 Sanofi Aventis Sa Derives de 1-benzylpyrazole, leur preparation et leur application en therapeutique
ES2534900T3 (es) * 2007-07-30 2015-04-30 Zynerba Pharmaceuticals, Inc. Profármacos de cannabidiol, composiciones que comprenden los profármacos de cannabidiol y métodos de uso de los mismos
US8367714B2 (en) * 2007-08-28 2013-02-05 Vanderbilt University Cannabinoid receptor targeted agent
US8133904B2 (en) * 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
AU2008300631A1 (en) 2007-09-20 2009-03-26 Abbott Healthcare Products B.V. 5-aryl-4,5-dihydro-(1H)-pyrazoles as cannabinoid CB1
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
US10053444B2 (en) 2009-02-19 2018-08-21 University Of Connecticut Cannabinergic nitrate esters and related analogs
EP2311443A1 (en) * 2009-10-15 2011-04-20 Rheinische Friedrich-Wilhelms-Universität Pharmaceutical composition containing cannabinoid-receptor 2 antagonists
CN102329192A (zh) * 2011-09-30 2012-01-25 山东天一化学股份有限公司 溴化苄的合成方法
PE20170664A1 (es) * 2014-06-06 2017-06-10 Res Triangle Inst Agonistas del receptor de apelina(apj) y usos de los mismos
AU2016277126A1 (en) 2015-06-12 2017-12-14 Vettore, LLC MCT4 inhibitors for treating disease
CN110114351B (zh) 2016-12-12 2022-09-20 维托尔股份有限公司 Mct4的杂环抑制剂
US10420089B2 (en) 2017-08-10 2019-09-17 At&T Intellectual Property I, L.P. Adaptive two-stage downlink control channel structure for code block group based fifth generation (5G) or other next generation systems
CA3125847A1 (en) 2020-07-27 2022-01-27 Makscientific, Llc Process for making biologically active compounds and intermediates thereof
US12054480B2 (en) 2020-07-31 2024-08-06 Makscientific, Llc Compounds for treating cannabinoid toxicity and acute cannabinoid overdose

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2711140B1 (fr) * 1993-10-12 1996-01-05 Sanofi Sa 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
IL124801A0 (en) 1999-01-26
CN1101813C (zh) 2003-02-19
US5925768A (en) 1999-07-20
TW402594B (en) 2000-08-21
IS4765A (is) 1998-06-08
FR2742148B1 (fr) 1999-10-22
DE69607484T2 (de) 2000-10-26
SK283706B6 (sk) 2003-12-02
CZ294307B6 (cs) 2004-11-10
PT868420E (pt) 2000-08-31
EP0885889A3 (fr) 1999-01-27
KR100488610B1 (ko) 2005-09-26
BR9611986A (pt) 1999-02-17
EE9800171A (et) 1998-12-15
EP0885889A2 (fr) 1998-12-23
ATE191211T1 (de) 2000-04-15
AR004364A1 (es) 1998-11-04
WO1997021682A1 (fr) 1997-06-19
AU1101097A (en) 1997-07-03
CA2239489C (en) 2006-05-09
SI0868420T1 (en) 2000-10-31
IL124801A (en) 2004-07-25
NO310683B1 (no) 2001-08-13
SK75898A3 (en) 1999-01-11
NO982589D0 (no) 1998-06-05
ZA9610299B (en) 1997-06-18
NO982589L (no) 1998-08-03
FR2742148A1 (fr) 1997-06-13
HUP9901244A2 (hu) 1999-08-30
AU718763B2 (en) 2000-04-20
KR19990072004A (ko) 1999-09-27
CN1207731A (zh) 1999-02-10
DE69607484D1 (de) 2000-05-04
MY115228A (en) 2003-04-30
EP0868420A1 (fr) 1998-10-07
ES2148820T3 (es) 2000-10-16
CZ177598A3 (cs) 1998-10-14
EP0868420B1 (fr) 2000-03-29
GR3033626T3 (en) 2000-10-31
JP3510270B2 (ja) 2004-03-22
PL327177A1 (en) 1998-11-23
JP2000502080A (ja) 2000-02-22
DK0868420T3 (da) 2000-08-21
MX9804565A (es) 1998-09-30
UA44913C2 (uk) 2002-03-15
CA2239489A1 (en) 1997-06-19
RU2170230C2 (ru) 2001-07-10
HUP9901244A3 (en) 2000-12-28
TR199801041T2 (xx) 1998-08-21
PL186466B1 (pl) 2004-01-30
NZ323962A (en) 1999-05-28

Similar Documents

Publication Publication Date Title
EE9800171A (et) 3-pürasoolkarboksamiidi derivaadid, mis omavad afiinsust kannabinoidretseptori suhtes
DE60023167D1 (de) Pyrazol-derivate als cannabinoidrezeptor-antagonisten
DE59511103D1 (de) 1-h-3-aryl-pyrrolidin-2,4-dion-derivate als schädlingsbekämpfungsmittel
EE9800227A (et) 17ß-karboksü-, karbotio- ja amiidandrostaanide laktoonderivaadid
NO992400D0 (no) Nye substituerte pyrazolderivater
DE69636444D1 (de) Protokollunabhängige, anpassungsfähige Netzwerkschnittstelle
EE200000089A (et) Sidesüsteem, mis sisaldab vahendid Interneti aadresside edastamiseks SMS-teenuse abil
PT1000048E (pt) Derivados substituidos do 1,2,3,4-tetrahidronaftaleno
TR199600883A2 (tr) Pürin-6-on türevleri.
PT921125E (pt) Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
NO20001698D0 (no) Fremgangsmåte for styring av stempelbevegelse, og tilhørende balanseorgan
NO974043L (no) Indolderivater som EAA-antagonister
MA26554A1 (fr) Derives d-homo-9, 10-secocholesta-23-yne-3,25-diol
DE59607332D1 (de) Antineurodegenerativ wirksame 10-Aminoaliphatyl-dibenz- b,f oxepine
BR9606950A (pt) Derivados de pirazol
ATE241599T1 (de) 25-hydroxy-16-ene-26,27-bishome-cholecalcerifer l derivate
BR9604847A (pt) Derivados de pirazol
FI950776L (fi) Henkil¦kohtainen tietoliikennejärjestelmä
FI970833L (fi) Dihydro-2,3-bentsodiatsepiinijohdannaiset
BR9607749A (pt) Derivados de pirazol
FI972862A7 (fi) Uudet stafylokinaasijohdannaiset
ES1032571Y (es) Gafa,
FI954065L (fi) Dihydro-2,3-bentsodiatsepiinijohdannaisen fyysinen olomuoto
NL1000212C2 (nl) Scharniersysteem.
FI960615A7 (fi) 1-(2-(substituoitu-vinyyli))-5H-2,3-bentsodiatsepiinijohdannaiset

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20101206